BioCryst Pharma To Present Rapivab Trial Results For Treatment Of Influenza

(RTTNews) - BioCryst Pharmaceuticals Inc.(BCRX) announced that clinical trial results related to its investigational drug RAPIVAB or peramivir injection, an intravenous (I.V.) neuraminidase inhibitor for the treatment of influenza, will be presented at the IDWeek Conference in Philadelphia October 8-12, 2014.

The New Drug Application or NDA for the indication of treatment of acute uncomplicated influenza in adults is currently under regulatory review by the FDA, with a PDUFA (Prescription Drug User Fee Act) action date of December 23, 2014.

RAPIVAB is a potent, intravenously administered, investigational anti-viral agent that rapidly delivers high plasma concentrations to the sites of influenza infection. If approved, RAPIVAB would be the first and only one-dose intravenous treatment for acute, uncomplicated influenza in the U.S.

In laboratory tests, RAPIVAB has shown activity against multiple influenza strains, including H7N9 and pandemic H1N1 swine flu viral strains. RAPIVAB was developed under a $234.8 million contract from BARDA/HHS.

In January 2010, Shionogi & Co., Ltd. launched peramivir in Japan under the name RAPIACTA to treat patients with influenza and in August 2010, Green Cross Corporation announced that it had received marketing and manufacturing authorization for peramivir in Korea to treat patients with influenza A & B viruses, including H1N1 and avian influenza.